NASDAQ:TGTX

Tg Therapeutics Stock Predictions

etoro logo Buy TGTX
*Your capital is at risk
$40.11
+3.47 (+9.47%)
At Close: Jun 03, 2026
Currently predicting for Thu, 4 Jun 2026

TGTX Prediction Chart

TGTX Predictions History

Latest community submissions for TGTX.
Predictor Target Session Target Price Result Direction Accuracy Score
JS JS Pro
Aug 13, 2020 $19.29 -5.35% $20.38 X 94.65% 1
sander7100 yo bro sander7100 yo bro Pro @sander7100yobro.167552
Aug 7, 2020 $16.60 -20.95% $21.00 X 79.05% 0
JS JS Pro
Aug 7, 2020 $21.03 +0.14% $21.00 X 99.86% 6
iHustle84 iHustle84 Pro
Aug 7, 2020 $19.67 -6.33% $21.00 X 93.67% 0
2poJeff 2poJeff Pro
Aug 7, 2020 $20.73 -1.29% $21.00 X 98.71% 1
JS JS Pro
Feb 18, 2020 $16.04 +1.13% $15.86 X 98.87% 2
Greg Keown Greg Keown @GregKeown.140108
Feb 18, 2020 $15.78 -0.50% $15.86 X 99.50% 3
joe1234 joe1234 Pro
Jun 10, 2019 $7.75 +8.09% $7.17 X 91.91% 0
joe1234 joe1234 Pro
May 14, 2019 $6.51 -4.55% $6.82 X 95.45% 0
May 7, 2019 $8.08 +1.39% $7.97 X 98.61% 1
Click to get the best stock tips daily for free!
Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for TGTX with a full price path, not just a one-day call.
  • Price path
  • Approved predictor
  • 3-month horizon
ABOUT TG THERAPEUTICS
TG Therapeutics
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbra...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE